Soham Sankaran
@soh.am
I run @popvax.com (https://popvax.com). We develop mRNA vaccines using computational protein design, including a broadly-protective COVID-19 vax to preempt new variants. I write at https://infinitesunrise.com, and I used to build robots (https://soh.am).
I'm delighted to announce that PopVax (@popvax.com) has been awarded $2M by the US Biomedical Advanced Research and Development Authority (@bardagov.bsky.social) as a winner of the first stage of BARDA’s Patch Forward Prize for our seasonal influenza vaccine, along with our partner LTS. (1/12)
February 10, 2025 at 1:03 PM
I'm delighted to announce that PopVax (@popvax.com) has been awarded $2M by the US Biomedical Advanced Research and Development Authority (@bardagov.bsky.social) as a winner of the first stage of BARDA’s Patch Forward Prize for our seasonal influenza vaccine, along with our partner LTS. (1/12)
We also have an H5N1 influenza vaccine candidate that elicits robust antibody responses against both the same strain of H5N1 that it is based on as well as other distinct H5N1 strains in mice.
January 3, 2025 at 2:50 PM
We also have an H5N1 influenza vaccine candidate that elicits robust antibody responses against both the same strain of H5N1 that it is based on as well as other distinct H5N1 strains in mice.
Our vaccine candidate also elicits as much as 250x greater antibody response in mice against seasonal strains compared with a seasonal influenza vaccine from the global market leader.
January 3, 2025 at 2:50 PM
Our vaccine candidate also elicits as much as 250x greater antibody response in mice against seasonal strains compared with a seasonal influenza vaccine from the global market leader.